Logo image of CSTE

CAESARSTONE LTD (CSTE) Stock Fundamental Analysis

NASDAQ:CSTE - Nasdaq - IL0011259137 - Common Stock - Currency: USD

1.72  +0.04 (+2.38%)

Fundamental Rating

2

Overall CSTE gets a fundamental rating of 2 out of 10. We evaluated CSTE against 41 industry peers in the Building Products industry. While CSTE seems to be doing ok healthwise, there are quite some concerns on its profitability. CSTE has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

CSTE had negative earnings in the past year.
In the past year CSTE had a positive cash flow from operations.
In multiple years CSTE reported negative net income over the last 5 years.
CSTE had a positive operating cash flow in 4 of the past 5 years.
CSTE Yearly Net Income VS EBIT VS OCF VS FCFCSTE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

1.2 Ratios

CSTE has a worse Return On Assets (-8.68%) than 82.93% of its industry peers.
CSTE has a worse Return On Equity (-17.69%) than 80.49% of its industry peers.
Industry RankSector Rank
ROA -8.68%
ROE -17.69%
ROIC N/A
ROA(3y)-11.12%
ROA(5y)-6.06%
ROE(3y)-20.4%
ROE(5y)-11.19%
ROIC(3y)N/A
ROIC(5y)N/A
CSTE Yearly ROA, ROE, ROICCSTE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20 -30

1.3 Margins

CSTE's Gross Margin of 20.93% is on the low side compared to the rest of the industry. CSTE is outperformed by 75.61% of its industry peers.
In the last couple of years the Gross Margin of CSTE has declined.
The Profit Margin and Operating Margin are not available for CSTE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 20.93%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.44%
GM growth 5Y-4.33%
CSTE Yearly Profit, Operating, Gross MarginsCSTE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 30 40

4

2. Health

2.1 Basic Checks

CSTE does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CSTE has about the same amount of shares outstanding.
CSTE has more shares outstanding than it did 5 years ago.
CSTE has a better debt/assets ratio than last year.
CSTE Yearly Shares OutstandingCSTE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
CSTE Yearly Total Debt VS Total AssetsCSTE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

CSTE has an Altman-Z score of 1.47. This is a bad value and indicates that CSTE is not financially healthy and even has some risk of bankruptcy.
CSTE has a worse Altman-Z score (1.47) than 87.80% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that CSTE is not too dependend on debt financing.
The Debt to Equity ratio of CSTE (0.00) is better than 85.37% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.47
ROIC/WACCN/A
WACC8.82%
CSTE Yearly LT Debt VS Equity VS FCFCSTE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M

2.3 Liquidity

CSTE has a Current Ratio of 2.22. This indicates that CSTE is financially healthy and has no problem in meeting its short term obligations.
CSTE has a better Current ratio (2.22) than 60.98% of its industry peers.
CSTE has a Quick Ratio of 1.46. This is a normal value and indicates that CSTE is financially healthy and should not expect problems in meeting its short term obligations.
CSTE has a Quick ratio (1.46) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 2.22
Quick Ratio 1.46
CSTE Yearly Current Assets VS Current LiabilitesCSTE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 21.54% over the past year.
CSTE shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -20.35%.
The Revenue has been decreasing by -4.09% on average over the past years.
EPS 1Y (TTM)21.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-123.08%
Revenue 1Y (TTM)-20.35%
Revenue growth 3Y-11.71%
Revenue growth 5Y-4.09%
Sales Q2Q%-15.84%

3.2 Future

CSTE is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.51% yearly.
CSTE is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -0.38% yearly.
EPS Next Y-0.81%
EPS Next 2Y13.51%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-6.9%
Revenue Next 2Y-0.38%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CSTE Yearly Revenue VS EstimatesCSTE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 200M 400M 600M
CSTE Yearly EPS VS EstimatesCSTE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 1 -1 2

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CSTE. In the last year negative earnings were reported.
Also next year CSTE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CSTE Price Earnings VS Forward Price EarningsCSTE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CSTE Per share dataCSTE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8 10

4.3 Compensation for Growth

CSTE's earnings are expected to grow with 13.51% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.51%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for CSTE!.
Industry RankSector Rank
Dividend Yield N/A

CAESARSTONE LTD

NASDAQ:CSTE (7/21/2025, 11:43:21 AM)

1.72

+0.04 (+2.38%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryBuilding Products
Earnings (Last)05-07 2025-05-07/bmo
Earnings (Next)08-06 2025-08-06/bmo
Inst Owners36.63%
Inst Owner Change0%
Ins Owners1.65%
Ins Owner ChangeN/A
Market Cap59.44M
Analysts82.86
Price Target4.08 (137.21%)
Short Float %0.38%
Short Ratio0.46
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-19.02%
Min EPS beat(2)-49.19%
Max EPS beat(2)11.15%
EPS beat(4)2
Avg EPS beat(4)-17.78%
Min EPS beat(4)-49.19%
Max EPS beat(4)11.15%
EPS beat(8)3
Avg EPS beat(8)-168.56%
EPS beat(12)3
Avg EPS beat(12)-232.83%
EPS beat(16)6
Avg EPS beat(16)-163.56%
Revenue beat(2)1
Avg Revenue beat(2)-1.43%
Min Revenue beat(2)-3.48%
Max Revenue beat(2)0.62%
Revenue beat(4)1
Avg Revenue beat(4)-5.2%
Min Revenue beat(4)-11.77%
Max Revenue beat(4)0.62%
Revenue beat(8)2
Avg Revenue beat(8)-6.26%
Revenue beat(12)2
Avg Revenue beat(12)-5.9%
Revenue beat(16)4
Avg Revenue beat(16)-3.52%
PT rev (1m)0%
PT rev (3m)-20%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-5.88%
EPS NY rev (1m)0%
EPS NY rev (3m)-13.33%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.64%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-3.64%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.14
P/FCF N/A
P/OCF 7.39
P/B 0.22
P/tB 0.22
EV/EBITDA N/A
EPS(TTM)-1.02
EYN/A
EPS(NY)-0.61
Fwd EYN/A
FCF(TTM)-0.04
FCFYN/A
OCF(TTM)0.23
OCFY13.53%
SpS12.28
BVpS7.66
TBVpS7.66
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -8.68%
ROE -17.69%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 20.93%
FCFM N/A
ROA(3y)-11.12%
ROA(5y)-6.06%
ROE(3y)-20.4%
ROE(5y)-11.19%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.44%
GM growth 5Y-4.33%
F-Score5
Asset Turnover0.79
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 57.35%
Cap/Sales 2.19%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.22
Quick Ratio 1.46
Altman-Z 1.47
F-Score5
WACC8.82%
ROIC/WACCN/A
Cap/Depr(3y)49.02%
Cap/Depr(5y)60.64%
Cap/Sales(3y)2.3%
Cap/Sales(5y)3.17%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-123.08%
EPS Next Y-0.81%
EPS Next 2Y13.51%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-20.35%
Revenue growth 3Y-11.71%
Revenue growth 5Y-4.09%
Sales Q2Q%-15.84%
Revenue Next Year-6.9%
Revenue Next 2Y-0.38%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y5.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year37.97%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y82.67%
FCF growth 3YN/A
FCF growth 5Y-18.43%
OCF growth 1Y1.81%
OCF growth 3Y15.48%
OCF growth 5Y-17.42%